// App-Quantinova.ai

: Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.

Researchers

Presenter

  • Guru Sonpavde

Principal Investigators

  • Daniel Hennessy

  • Juliane Manitz

  • Guenter Niegisch

  • Thomas Powles

  • Jonathan E. Rosenberg

  • Dean F. Bajorin

  • Andrea B. Apolo

  • Gregory Russell Pond

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • EMD Serono, Rockland, MD

  • EMD Serono, Inc, Billerica, MA

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Barts Cancer Institute, Royal Free NHS trust, St. Bartholomew’s Hospital, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • McMaster University, Hamilton, ON, Canada

Locations

  • United States

  • Germany

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved